Posted by Michael Wonder on 17 Sep 2022
Highlights from the 12-15 September 2022 CHMP meeting
16 September 2022 - 12 new medicines recommended for approval.
The CHMP recommended granting a marketing authorisation for Beyfortus (nirsevimab) intended for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants during their first respiratory syncytial virus season (when there is a risk of respiratory syncytial virus infection in the community).
